Literature DB >> 10607765

Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy.

J Syrjänen1, J Mustonen, A Pasternack.   

Abstract

BACKGROUND: The prognosis of IgA nephropathy (IgAN) is variable and about 10-20% of patients progress to end-stage renal disease (ESRD) in 10 years. Hypertension, proteinuria and renal insufficiency at the time of diagnosis are risk factors associated with poor prognosis. Lipid abnormalities may have a role in the progression of glomerulonephritides, and glomerulosclerosis and atherosclerosis may have similar pathophysiological mechanisms. We therefore evaluated factors associated with cardiovascular diseases, especially hypercholesterolaemia, hypertriglyceridaemia, and hyperuricaemia, as predictors of the progression of IgAN.
METHODS: A total of 223 patients with IgAN (141 men, 82 women; median age 41 years, range 8-78 years) were studied. The following parameters were recorded at the time of renal biopsy: presence of hypertension or diabetes, smoking habits, body mass index (BMI), serum creatinine, total and HDL-cholesterol, triglycerides, and urate and 24-h urinary protein excretion. The patients were followed up for 0.2-17 years (median 10 years) with respect to progression of renal disease defined as elevation of serum creatinine above 125 micromol/l in men or 105 micromol/l in women, and over 20% elevation from baseline.
RESULTS: Forty-one patients (18%) showed progression. Hypertriglyceridaemia and hyperuricaemia were significantly more common at the time of renal biopsy in patients with progressive than in those with stable disease. In patients with normal renal function at the time of diagnosis initial hypertriglyceridaemia, hyperuricaemia, hypertension and proteinuria were independent risk factors for progression of IgAN in the Cox regression hazard model.
CONCLUSIONS: Our results show that hypertriglyceridaemia and hyperuricaemia at the time of diagnosis are important, previously underestimated predictors of poor outcome in IgAN, although causality between these factors and progression cannot be inferred from the present study.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10607765     DOI: 10.1093/ndt/15.1.34

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  73 in total

1.  Progression of IgA nephropathy under current therapy regimen in a Chinese population.

Authors:  Xiangling Li; Youxia Liu; Jicheng Lv; Sufang Shi; Lijun Liu; Yuqing Chen; Hong Zhang
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

Review 2.  Uric acid as a target of therapy in CKD.

Authors:  Diana I Jalal; Michel Chonchol; Wei Chen; Giovanni Targher
Journal:  Am J Kidney Dis       Date:  2012-10-09       Impact factor: 8.860

3.  Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study.

Authors:  Jaana Ronkainen; Marja Ala-Houhala; Helena Autio-Harmainen; Timo Jahnukainen; Olli Koskimies; Jussi Merenmies; Jukka Mustonen; Timo Ormälä; Juha Turtinen; Matti Nuutinen
Journal:  Pediatr Nephrol       Date:  2006-07-13       Impact factor: 3.714

4.  Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial.

Authors:  Yongjun Shi; Wei Chen; Diana Jalal; Zhibin Li; Wenfang Chen; Haiping Mao; Qiongqiong Yang; Richard J Johnson; Xueqing Yu
Journal:  Kidney Blood Press Res       Date:  2011-11-23       Impact factor: 2.687

Review 5.  Pathogenesis of glomerular haematuria.

Authors:  Claudia Yuste; Eduardo Gutierrez; Angel Manuel Sevillano; Alfonso Rubio-Navarro; Juan Manuel Amaro-Villalobos; Alberto Ortiz; Jesus Egido; Manuel Praga; Juan Antonio Moreno
Journal:  World J Nephrol       Date:  2015-05-06

Review 6.  Uric acid as a factor in the metabolic syndrome.

Authors:  Rodolfo Leão Borges; Artur Beltrame Ribeiro; Maria Teresa Zanella; Marcelo Costa Batista
Journal:  Curr Hypertens Rep       Date:  2010-04       Impact factor: 5.369

7.  Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China.

Authors:  Wei Chen; Weiqing Chen; Hui Wang; Xiuqing Dong; Qinghua Liu; Haiping Mao; Jiaqing Tan; Jianxiong Lin; Feiyu Zhou; Ning Luo; Huijuan He; Richard J Johnson; Shu-Feng Zhou; Xueqing Yu
Journal:  Nephrol Dial Transplant       Date:  2008-10-24       Impact factor: 5.992

8.  Urinary transforming growth factor beta1 in children and adolescents with congenital solitary kidney.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz; Katarzyna Taranta-Janusz
Journal:  Pediatr Nephrol       Date:  2008-12-02       Impact factor: 3.714

9.  Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010.

Authors:  Stephen P Juraschek; Lara C Kovell; Edgar R Miller; Allan C Gelber
Journal:  Semin Arthritis Rheum       Date:  2013-01-09       Impact factor: 5.532

10.  Association of a polymorphism in a gene encoding a urate transporter with CKD progression.

Authors:  Alessandra Testa; Francesca Mallamaci; Belinda Spoto; Anna Pisano; Maria Cristina Sanguedolce; Giovanni Tripepi; Daniela Leonardis; Carmine Zoccali
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-17       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.